Small Cell Lung Cancer Flashcards
1
Q
How much of lung cancer does small cell lung cancer account for?
A
- 15-20%
- Early spread
- Patients often present with extensive disease (2/3)
2
Q
How are small cell lung cancers characterised?
A
- Rapid growth (mitotic rate)
- Response to chemo and RT
- Resistance to treatment is also common
3
Q
How can T1-T2 patients be treated?
A
- Very few present at this stage
- Could have surgery alone
4
Q
How can T3 and T4, with M0 be treated?
A
- Concurrent chemo-RT (bidaily) - CONVERT
- Sequential if not fit enough
5
Q
What are the requirements for bidaily RT with concurrent chemo?
A
- PS 0-1
- Or disease which can be encompasses in a radical thoracic RT volume
- Once daily is an alternative
- PCI should be offered
6
Q
What are the options for extensive-stage disease?
A
- BSC
- Pt-based chemo (if fit enough)
- Assessed prior to each cycle, max of 6 cycles depending on response and toxicity
- Thoracic RT with PCI could be considered
- Palliative RT
7
Q
What is the guidance for PCI?
A
- 25Gy / 10# / 2 weeks
- for limited stage or those with a response
8
Q
What is the trial evidence relating to PCI?
A
- 2019 NICE said PCI should be immediately after
- Is there a risk in quality of life
- Should active surveillance be an option
